Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

nork Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales, S., de la Haba-Rodríguez, J.
Argitaratua 2013

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

nork Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., Matera, J., Azarnia, N., Hudis, C. A., Rozencweig, M.
Argitaratua izan da Ann Oncol (2014)

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

nork Rivera, F., Andres, R., Felip, E., Garcia-Campelo, R., Lianes, P., Llombart, A., Piera, J. M., Puente, J., Rodriguez, C. A., Vera, R., Virizuela, J. A., Martin, M., Garrido, P.
Argitaratua izan da Clin Transl Oncol (2016)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

nork Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V.F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R.H., Matera, J., Azarnia, N., Hudis, C.A., Rozencweig, M.
Argitaratua izan da Ann Oncol (2019)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

nork Feliu, J, Safont, M J, Salud, A, Losa, F, García-Girón, C, Bosch, C, Escudero, P, López, R, Madroñal, C, Bolaños, M, Gil, M, Llombart, A, Castro-Carpeño, J, González-Barón, M
Argitaratua 2010

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

nork Colomer, R, Monzo, M, Tusquets, I, Rifa, J, Baena, JM, Barnadas, A, Calvo, L, Carabantes, F, Crespo, C, Muñoz, M, Llombart, A, Plazaola, A, Alba, E, Fuster, D, Gilabert, M, Lloveras, B
Argitaratua izan da Breast Cancer Res (2005)

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

nork Salvador, J., Aparicio, J., Baron, F. J., García-Campelo, R., Garcia-Carbonero, R., Lianes, P., Llombart, A., Isla, D., Piera, J. M., Muñoz, M., Puente, J., Rivera, F., Rodríguez, C. A., Virizuela, J. A., Martín, M., Garrido, P.
Argitaratua izan da Clin Transl Oncol (2017)

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

nork Salvador, J., Urtasun, J. A., Duart, F. J. B., García-Campelo, R., Carbonero, R. G., Lianes, P., Llombart, A., Casado, D. I., Piera, J. M., Mateu, M. M., Puente, J., Rivera, F., Rodríguez, C. A., Virizuela, J. A., Martín, M., Garrido, P.
Argitaratua izan da Clin Transl Oncol (2016)

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

nork Barnadas, A., Muñoz, M., Margelí, M., Chacón, J. I., Cassinello, J., Antolin, S., Adrover, E., Ramos, M., Carrasco, E., Jimeno, M. A., Ojeda, B., González, X., González, S., Constenla, M., Florián, J., Miguel, A., Llombart, A., Lluch, A., Ruiz-Borrego, M., Colomer, R., Del Barco, S.
Argitaratua izan da J Patient Rep Outcomes (2019)

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

nork Colomer, R., Alba, E., González-Martin, A., Paz-Ares, L., Martín, M., Llombart, A., Rodríguez Lescure, Á., Salvador, J., Albanell, J., Isla, D., Lomas, M., Rodríguez, C. A., Trigo, J. M., Germà, J. R., Bellmunt, J., Tabernero, J., Rosell, R., Aranda, E., Cubedo, R., Baselga, J.
Argitaratua 2010